ARCT Arcturus Therapeutics Holdings Inc

Price (delayed)

$51.93

Market cap

$1.37B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.5

Enterprise value

$995.26M

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ ...

Highlights
Arcturus Therapeutics Holdings's debt has decreased by 3.4% QoQ
ARCT's quick ratio is down by 30% since the previous quarter but it is up by 2.2% year-on-year
The company's EPS has shrunk by 150% YoY and by 31% QoQ
The net income is down by 37% since the previous quarter

Key stats

What are the main financial stats of ARCT
Market
Shares outstanding
26.33M
Market cap
$1.37B
Enterprise value
$995.26M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.47
Price to sales (P/S)
157.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
114.41
Earnings
Revenue
$8.7M
EBIT
-$162.07M
EBITDA
-$160.99M
Free cash flow
-$100.06M
Per share
EPS
-$6.5
Free cash flow per share
-$3.8
Book value per share
$11.61
Revenue per share
$0.33
TBVPS
$17.05
Balance sheet
Total assets
$448.81M
Total liabilities
$143.17M
Debt
$61.67M
Equity
$305.65M
Working capital
$367.27M
Liquidity
Debt to equity
0.2
Current ratio
6.19
Quick ratio
6.16
Net debt/EBITDA
2.31
Margins
EBITDA margin
-1,850.6%
Gross margin
100%
Net margin
-1,874.2%
Operating margin
-1,878.4%
Efficiency
Return on assets
-37.7%
Return on equity
-49.5%
Return on invested capital
-3,255.2%
Return on capital employed
-42.9%
Return on sales
-1,863.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARCT stock price

How has the Arcturus Therapeutics Holdings stock price performed over time
Intraday
-4.8%
1 week
-4.63%
1 month
1.35%
1 year
38.52%
YTD
19.71%
QTD
53.46%

Financial performance

How have Arcturus Therapeutics Holdings's revenue and profit performed over time
Revenue
$8.7M
Gross profit
$8.7M
Operating income
-$163.41M
Net income
-$163.04M
Gross margin
100%
Net margin
-1,874.2%
Arcturus Therapeutics Holdings's net margin has decreased by 42% QoQ
Arcturus Therapeutics Holdings's operating margin has decreased by 42% QoQ
The net income is down by 37% since the previous quarter
Arcturus Therapeutics Holdings's operating income has decreased by 36% QoQ

Growth

What is Arcturus Therapeutics Holdings's growth rate over time

Valuation

What is Arcturus Therapeutics Holdings stock price valuation
P/E
N/A
P/B
4.47
P/S
157.14
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
114.41
The company's EPS has shrunk by 150% YoY and by 31% QoQ
ARCT's P/B is 47% higher than its last 4 quarters average of 3.2
ARCT's equity is down by 13% since the previous quarter
ARCT's price to sales (P/S) is 61% higher than its last 4 quarters average of 102.7
The revenue has declined by 23% year-on-year and by 3.6% since the previous quarter

Efficiency

How efficient is Arcturus Therapeutics Holdings business performance
Arcturus Therapeutics Holdings's ROIC has plunged by 65% from the previous quarter
The company's return on equity rose by 45% YoY but it fell by 15% QoQ
The company's return on sales fell by 42% QoQ
The ROA has decreased by 14% QoQ but it has increased by 4.1% YoY

Dividends

What is ARCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARCT.

Financial health

How did Arcturus Therapeutics Holdings financials performed over time
Arcturus Therapeutics Holdings's total assets has surged by 199% YoY but it has decreased by 7% QoQ
Arcturus Therapeutics Holdings's total liabilities has surged by 153% YoY and by 11% QoQ
Arcturus Therapeutics Holdings's debt is 80% lower than its equity
ARCT's equity is down by 13% since the previous quarter
The debt to equity has increased by 11% from the previous quarter but it has decreased by 4.8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.